Aflibercept (AFL) vs. ramucirumab (RAM) -based therapy in patients with advanced colorectal cancer: Efficacy comparison using real-world data evidence from TriNetX platform.

• DOI: 10.1200/jco.2025.43.4_suppl.71
• Publication Date: 2025-01-27T14:34:47Z
• Authors: Jesus Rodriguez-P...; Gema Hernández; Lisardo Ugidos; Alejandro Parralejo; Juan Diego Rodrig...; Juan Jose Serrano; Angel Ayuso
• Keywords: Ramucirumab; Aflibercept; Real world data; Regorafenib

71 Background: FOLFIRI in combination with Aflibercept (AFL) or Ramucirumab (RAM) prolongs overall survival compared alone patients advanced colorectal cancer (aCCR) as second-line therapy, however, there are no comparative studies between them. Methods: Utilizing the TriNetX Global Collaborative Network, a platform that operates globally based on anonymized and aggregated clinical data, sample of aCCR from 128 healthcare organizations (HCOs) who met initial criteria was selected. 5-year (OS) analyzed these cohorts using Kaplan-Meier analysis. Hazard Ratio (HR) its 95% confidence interval (95%CI) were calculated to evaluate difference cohorts. Propensity Score Matching (PSM) used balance age, gender, race mitigating possible cofounding variables. All statistical analyses conducted utilizing Analytics function online research platform. Results: A total 1046 study included our study. 523 received AFL 523r RAM-based therapy. Patients treated showed significant better OS RAM, both previous PSM before (post-PMS median 430 days vs 317 days, HR 0.797, 95%CI 0.683-0.930). Conclusions: In this study, Real World superior results treatment. To date is largest comparison two therapeutic options.